IP Library Granted Patent US 10,485,898
Granted Patent B2
US 10,485,898 · App. 15/460,899 · Granted Nov 26, 2019

High strength biomedical materials

Inventors: James F. Biggins (Waltham, MA); Michael Bassett (Hampton, NH); Daniel Donahue (Somerville, MA)
Assignee: Access Vascular, Inc.
A61L29/041A61L17/10A61L27/16A61L27/56A61L29/02A61L29/049A61L29/146A61L29/16A61L29/18A61L33/007A61L33/064B29C48/00B29C48/78C08J9/0061C08J9/0066C08J9/28D01F1/08A61L2300/42A61L2400/12A61M25/005B29C48/05B29C48/865B29C67/0029B29K2105/04B29L2031/753C08J2201/03C08J2201/0546C08J2205/042C08J2205/044C08J2207/10C08J2329/04C08J2433/02D01F6/14D01F6/50
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,485,898
App. No.
15/460,899
Granted
Nov 26, 2019
Kind
B2
Abstract

High strength biomedical materials and processes for making the same are disclosed. Included in the disclosure are nanoporous hydrophilic solids that can be extruded with a high aspect ratio to make high strength medical catheters and other devices with lubricious and biocompatible surfaces.

Claims (29)

1. A hydrophilic porous solid tube, comprising:

a polymeric material formed by physically crosslinking at least one water soluble polymer to form the hydrophilic porous solid tube, wherein the hydrophilic porous solid tube comprises pores that each have a diameter of 1 μm or less,

wherein the hydrophilic porous solid tube has a solids content of 33% to 90% w/w at equilibrium water content (EWC) and a Young's modulus of 5-100 MPa at EWC, and wherein the hydrophilic porous solid tube is free of covalent crosslinks between the at least one water soluble polymer that forms the hydrophilic porous solid tube.

2. The hydrophilic porous solid tube of claim 1 having an aspect ratio of at least 10:1.

3. The hydrophilic porous solid tube of claim 1 having an aspect ratio of at least 50:1.

4. The hydrophilic porous solid tube of claim 1 wherein at least 50% w/w of the at least one water soluble polymer is poly(vinyl alcohol) (PVA).

5. The hydrophilic porous solid tube of claim 1 wherein the at least one water soluble polymer is selected from the group consisting of PVA, poly(acrylic acid), polyethylene glycol, and poly(vinyl pyrrolidone).

6. The hydrophilic porous solid tube of claim 1 wherein the at least one water soluble polymer comprises a first hydrophilic polymer and a second hydrophilic polymer, wherein the second hydrophilic polymer is present in an amount from 1 part to 1,000 parts relative to 10,000 parts of the first hydrophilic polymer.

7. The hydrophilic porous solid tube of claim 1 further comprising a radiopaque agent.

8. The hydrophilic porous solid tube of claim 1 wherein the Young's modulus is from 10 to 100 MPa at EWC.

9. The hydrophilic porous solid tube of claim 1 consisting essentially of the at least one water soluble polymer and a radiopaque agent.

10. The hydrophilic porous solid tube of claim 1 wherein a swelling of 50% w/w or less is achieved at EWC.

11. The hydrophilic porous solid tube of claim 1 wherein, at EWC, an outer diameter of the hydrophilic porous solid tube is from 0.02 to 0.50 inches and an inner diameter of the hydrophilic porous solid tube is from 0.01 to 0.40 inches, wherein the outer diameter is at least 0.001 inches larger than the inner diameter.

12. A catheter comprising

a hydrophilic porous solid tube formed by physically crosslinking at least one water soluble polymer to form the hydrophilic porous solid tube, wherein the hydrophilic porous solid tube comprises pores that each have a diameter of 1 μm or less,

wherein the hydrophilic porous solid tube having a solids content of 33% to 90% w/w at equilibrium water content (EWC) and a Young's modulus of 5-100 MPa at EWC wherein the hydrophilic porous solid tube is free of covalent crosslinks between the at least one water soluble polymer that forms the hydrophilic porous solid tube.

13. The catheter of claim 12 wherein the catheter is a central venous catheter.

14. The catheter of claim 12 wherein the catheter is a peripherally inserted central catheter (PICC).

15. The catheter of claim 12 wherein the catheter is a tunneled catheter, a dialysis catheter, a peripheral central catheter, a midline catheter, a peripheral catheter, a tunneled catheter, a dialysis access catheter, an urinary catheter, a neurological catheter, a peritoneal catheter, an intra-aortic balloon pump catheter, a diagnostic catheter, an interventional catheter, a drainage catheter, or a drug delivery catheter.

16. The catheter of claim 12 wherein the Young's modulus of the catheter is from 10 to 100 MPa at EWC.

17. The catheter of claim 12 wherein, at EWC, an outer diameter of the catheter is from 0.02 to 0.50 inches and an inner diameter of the tube is from 0.01 to 0.40 inches, wherein the outer diameter is at least 0.001 inches larger than the inner diameter.

18. The catheter of claim 12 having an aspect ratio of at least 10:1.

19. The catheter of claim 12 having an aspect ratio of at least 50:1.

20. The catheter of claim 12 wherein at least 50% w/w of the at least one water soluble polymer is poly(vinyl alcohol) (PVA).

21. The catheter of claim 12 wherein the at least one water soluble polymer is selected from the group consisting of PVA, poly(acrylic acid), polyethylene glycol, and poly(vinyl pyrrolidone).

22. The catheter of claim 12 wherein the at least one water soluble polymer comprises a first hydrophilic polymer and a second hydrophilic polymer, wherein the second hydrophilic polymer is present in an amount from 1 part to 1,000 parts relative to 10,000 parts of the first hydrophilic polymer.

23. The catheter of claim 12 , wherein the hydrophilic porous solid tube further comprises a radiopaque agent.

24. The catheter of claim 12 , wherein the hydrophilic porous solid tube consists essentially of the at least one water soluble polymer and a radiopaque agent.

25. The catheter of claim 12 wherein the catheter has a swelling of 50% w/w or less at EWC.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 23, 2019
From: BIGGINS, JAMES F.; BASSETT, MICHAEL; DONAHUE, DANIEL
To: ACCESS VASCULAR, INC.
Reel/Frame 050464/0214 →
Continuity (3)
Continuation 15388820 · Dec 22, 2016
Provisional Application 62271150 · Dec 22, 2015
Related Publication 20170182223A1 · Jun 29, 2017
Cited By (5)
US 12,194,198 US 12,350,405 US 12,383,658 US 12,383,659 US 12,533,485